26 Mar Minaris
Eytan Abraham, Ph.D., Chief Finacial Officer, Chief Commercial Officer
April 15 | 2:15pm | Salone dei Cavalieri, Section 2
Allendale, NJ
(Private)
A global vision for cell and gene therapies. The market growth of CGT demands experienced CDMO partners that have the track record, global footprint, end-to-end services, and platform technologies to enable us to reach more patients. CDMOs need to deliver, be good long-term partners, and establish and functionalize manufacturing and testing platforms that reduce COGS and vein-to-vein time, thus enabling scalable commercial manufacturing. Minaris Regenerative Medicine and WuXi Advanced Therapies are now owned by the Private Equity fund Altaris and are combining to become the largest and most experienced CGT focused CDMO globally, with 25 years of experience, 11 sites globally, 82 cleanrooms and 4 commercial sites in Japan, Germany and the U.S.A. This, coupled with extensive CT and Viral Vector development (Oxgene) manufacturing and testing capabilities enable Minaris Advanced Therapies to serve the needs of CGT Therapeutic companies at all stages and all geographies now and into the future. This unified global company will also streamline and derisk tech-transfers between sites through standardization of best in class digital and equipment solutions. We are creating a best-in-class global CGT CDMO that truly moves the needle for the industry, answering the call for a global, commercial ready, development and manufacturing partner that works with therapeutic companies to deliver Cell and Gene Therapies to more patients.
